Ethics in public health research: Anthrax vaccine and public health policy

American Journal of Public Health

Volumn 97, Issue 11, 2007, Pages 1945-1951

  Weiss, Martin Meyer ^a,b   Weiss, Peter D ^b   Weiss, Joseph B ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIBIOTIC AGENT; CIPROFLOXACIN; PENICILLIN G; ANTIINFECTIVE AGENT;

ANTHRAX; ATTITUDE TO HEALTH; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CENTER; HUMAN; MEDICAL ETHICS; MEDICAL RESEARCH; NONHUMAN; ORGANIZATION AND MANAGEMENT; PROPHYLAXIS; PUBLIC HEALTH SERVICE; REVIEW; TREATMENT DURATION; VACCINATION; ANIMAL; BIOTECHNOLOGY; DRUG DESIGN; HAMSTER; MASS IMMUNIZATION; ORGANIZATION; POLICY; POLITICS; PUBLIC HEALTH; SYRIAN HAMSTER; UNITED STATES;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTI-BACTERIAL AGENTS; BIOTECHNOLOGY; BIOTERRORISM; CRICETINAE; DRUG DESIGN; FEDERAL GOVERNMENT; HEALTH POLICY; HUMANS; INSTITUTE OF MEDICINE (U.S.); MASS IMMUNIZATION; MESOCRICETUS; POLITICS; PRIVATE SECTOR; PUBLIC HEALTH; PUBLIC POLICY; UNITED STATES; UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES;

EID: 35748936204     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2006.102749     Document Type: Review

References (78)

1. Centers for Disease Control and Prevention. Anthrax: what you need to know. Available at: http://www.bt.cdc.gov/agent/anthrax/needtoknow.asp. Accessed December 24, 2006.
2. Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL, eds. The Anthrax Vaccine: Is It Safe? Does It Work? Washington, DC: National Academies Press; 2002. Available at: http://www.nap.edu/books/0309083095/html. Accessed November 3, 2006.
3. Grabenstein JD. Anthrax vaccine: a review. Immunol Allergy Clin N Am. 2003;23:713-730.
4. Nass M. The Anthrax Vaccine Program: an analysis of the CDC's recommendations for vaccine use. Am J Public Health. 2002;92:715-721.
5. McDonald E, Langreth R. Spore wars. Forbes Global. June 6, 2005:36.
6. Lee C. Mandatory anthrax shots to return. Washington Post. October 17, 2006:A3.
7. Department of Health and Human Services, Food and Drug Administration. Biological products; bacterial vaccines and toxoids; implementation of efficacy review; anthrax vaccine adsorbed; final order. Docket No. 1980N-0208. Fed Reg. 2005;70:75180-75197.
8. Brachman P, Gold H, Plotkin S, Fekety F, Werrin M, Ingraham N. Field evaluations of a human anthrax vaccine. Am J Public Health. 1962;52:632-645.
9. Wang JY, Roehrl MH. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus and toxin. Med Immunol. 2005;4:4.
10. Pomerantsev AP, Staritsin NA, Mockov YV, Marinin LI. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine. 1997;15:1846-1850.
11. Turnbull C. Anthrax vaccines: past, present and future. Vaccine. 1991;9:533-539.
12. Little S, Knudson G. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun. 1986;52:509-512.
13. Department of Defense Anthrax Vaccine Immunization Program. Hearing Before the Committee on Armed Services, Senate Hearing No. 106-886, 106th Cong, 2nd Sess (April 13 and July 12, 2000).
14. Rosenberg H. Anthrax cloud's silver lining [transcript]. "20/20." ABC television. March 12, 1999.
15. General Accountability Office (GAO). Contract management: observations on DOD's financial relationship with the anthrax vaccine manufacturer. (Testimony given on June 30, 1999, National Security and International Affairs Division-99-214). Available at: http://www.fas.org/spp/starwars/gao/nsiad-99- 214.htm. Accessed December 11, 2006.
16. Pound E. A no-show vaccine - for a mere $126 million. Deal? US News & World Report. October 29, 2001:16.
17. Statement of Robert J. Lieberman, assistant inspector general for auditing, Department of Defense, before the Senate Committee on Armed Services on Defense Anthrax Vaccine Contracting, July 12, 2000. Available at: http://www.dodig.mil/fo/000712rl.pdf. Accessed September 2, 2006.
18. Food and Drug Administration. FDA Bioport Inspection of 1999. Available at: http://www.avip2001.net/OfficialDocuments_files/FDA_1999.htm. Accessed December 27, 2006.
19. Food and Drug Administration. FDA Bioport Inspection of 2000. Available at: http://www.avip2001.net/DOCS/FDA_Bioport001026.pdf. Accessed December 27, 2006.
20. Testimony on the anthrax vaccine by Kathryn C. Zoon, PhD, director, Center for Biologics Evaluation and Research, FDA, US Department of Health and Human Services, before the House Armed Services Subcommittee on Military Personnel, July 13, 2000. Available at: http://www.hhs.gov/asl/testify/t000713a. html. Accessed February 13, 2007.
21. Evans B. How a company cashed in on anthrax. Newport News Daily Press. December 7, 2005. Available at: http://www.dailypress.com/news/local/ dp-anth-day4-bioportdec06,0,1903057. story. Accessed July 20, 2006.
22. Maier T. Still a long wait for anthrax vaccine. Insight on the News. November 19, 2001:18.
23. Martin T. Pentagon assessing Bioport Review of contract with Lansing firm this month. Lansing State Journal. August 24, 2001:1A. Available at: http://www.milvacs.org/AVN/sonnie/news/24Aug01_LansingStJnl.htm. Accessed September 12, 2007.
24. Food and Drug Administration. FDA approves license supplements for anthrax vaccine. Available at: http://www.scienceblog.com/community/older/ archives/M/2/fda1299.htm. Accessed February 28, 2006.
25. Form S-1/A. Emergent BioSolutions Inc-EBS. Filed October 30, 2006. Available at: http://media.corporate-ir.net/media_files/irol/20/202582/irkit/ S1A.pdf. Accessed August 18, 2007.
26. Company incorporation, Netherlands Antilles. Available at: http://www.offshoreinfo.com/netherlands_antilles.htm. Accessed March 3, 2006.
27. Jones D. Muslim CEOs of US firms fight terrorism, "stop evil." USA Today. May 18, 2004:1B.
28. Mosk M. Protestors develop skepticism about campaign contributions. Washington Post. October 30, 2003:T2.
29. Maier T. Why BioPort got a shot in the arm - allegations of misconduct surround maker of anthrax vaccine. Insight. September 20, 1999:13. Available at: http://findarticles.com/p/articles/mi_m1571/is_35_15/ai_55927014. Accessed August 18, 2007.
30. Maier TW. Did the FBI make a rush to judgment? Insight on the News. April 15, 2003:28. Available at: http://www.findarticle.com/p/article/ mi_m/571/is_9_19itsai_10011690. Accessed June 30, 2006.
31. Lipton E. US cancels order for 75 million doses of anthrax vaccine. New York Times. December 20, 2006:A23.
32. Center for Responsive Politics. Lobbying database. Available at: http://www.opensecrets.org/lobbyists/clientsum.asp?txtname= Emergent+Biosolutions&ye. Accessed August 3, 2006.
33. Lipton E. Setbacks plague bid to stockpile bioterror drugs. New York Times. September 18, 2006:A1.
34. Department of Health and Human Services. HHS awards BioShield contract for AVA anthrax vaccine [news release]. May 6, 2005. Available at: http://www.os.dhhs.gov/news/press/2005pres/20050506.html. Accessed October 7, 2005.
35. Miller J. Anthrax vaccine maker calls finances shaky. New York Times. August 5, 2002:A10.
36. Rosenwald M. Anthrax vaccine supplier moves closer to initial public offering. Washington Post. November 11, 2006:D1.
37. US Securities and Exchange Commission. Form S-1. Registration statement under the Securities Act of 1933. Emergent Biosolutions Inc. Filed August 14, 2006. Available at: http://www.sec.gov/Archives/edgar/data/1367644/ 000095013306003817/w20323sv1.htm. Accessed December 27, 2006.
38. Emergent Biosolutions. Recent news releases. Available at: http://www.emergentbiosolutions.com/html/recentnews.aspx. Accessed January 1, 2007.
39. Offit P. Is the vaccine industry ailing? Medical News Today. May 10, 2005. Available at: http://www.medicalnewstoday.com/medicalnews.php?newsid= 24109. Accessed September 11, 2007.
40. Sloan FA, Berman S, Rosenbaum S, et al. The fragility of the US vaccine supply. N Engl J Med. 2004;351:2443-2447.
41. Cohen J, Marshall E. Vaccines for biodefense: a system in distress. Science. 2001;294:498.
42. Pollack A. Pfizer enters vaccine business with the purchase of a British company, PowderMed. New York Times. October 10, 2006:A4.
43. Department of Defense. Report on biological warfare vaccine research and development programs. July 2001. Available at: http:/www.defenselink.mil/pubs/ reportonbiologicalwarfaredefensevaccineRDPrgras-July2001.pdf. Accessed August 18, 2007.
44. Rand National Security Research Division. Gilmore Commission. Available at: http://www.rand.org/nsrd/terrpanel. Accessed August 24, 2006.
45. Committee on the Evaluation of Vaccine Purchase Financing in the United States. Financing Vaccines in the 21st Century: Assuring Access and Availability. Washington, DC: National Academies Press; 2003. Available at: http://www.nap.edu/openbook/0309089794/html/1.html. Accessed April 4, 2006.
46. Miller H, Kazman S. Federalize vaccine production? We'd be taking a shot in the dark. Hoover Digest. 2002. Available at: http://www.hooverdigest. org/022/miller.html. Accessed February 26, 2006.
47. Schwartz HK. The US vaccine supply. N Engl J Med. 2005;352:1046-1047.
48. Sidel V, Gould R, Cohen H. Bioterrorism preparedness: cooptation of public health? Med Glob Surviv. 2002;7:82-89.
49. Jefferson T. Bioterrorism and compulsory vaccination. BMJ. 2004;329:524-525.
50. Cohen HW, Gould RM, Sidel VW. The pitfalls of bioterrorism preparedness: the anthrax and smallpox experiences. Am J Public Health. 2004;94:1667-1671.
51. Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM Jr. Biological warfare: a historical perspective. JAMA. 1997;278:412-417.
52. Tucker JB. Historical trends related to bioterrorism: an empirical analysis. Emerg Infect Dis. 1999;5:498-504.
53. Keim P, Smith K, Keys C, Takahashi H, Kurata T, Kaufman A. Molecular investigation of the Aum Shinrikyo anthrax release in Kameido, Japan. J Clin Microbiol. 2001;39:4566-4567.
54. Epstein EJ. FBI overlooks foreign sources of anthrax. Wall Street Journal. December 24, 2001:A10. Available at: http://www.edwardjayepstein. com/archived/anthrax.htm. Accessed 27 March 27, 2005.
55. Tell D. Remember anthrax? Weekly Standard. April 29, 2002:22. Available at: http://www.ph.ucla.edu/epi/bioter/remeberanthrax.html. Accessed January 3, 2006.
56. Gugliotta G, Matsumoto G. FBI's theory on anthrax is doubted. Washington Post. October 28, 2002:A1. Available at: http://www.ph.ucla. edu/epi/bioter/fbitheorydoubted.html. Accessed November 2, 2005.
57. Beecher D. Forensic application of microbial culture analysis to identify mail intentionally contaminated with Bacillus anthracis spores. Appl Environ Microbiol. 2006;72:5304-5310.
58. Broad W. Anthrax not weapons grade, official says. New York Times. September 26, 2006:A16.
59. Inglesby T, O'Toole T, Henderson DA, Bartlett J, Ascher M, Eitzen E. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002;287:2236-2252.
60. Zilinskas R. Iraq's biological weapons: the past as future? JAMA. 1997;278:418-424.
61. Davis CJ. Nuclear blindness: an overview of the biological weapons programs of the former Soviet Union and Iraq. Emerg Infect Dis. 2000;5:509-512. Available at: http://www.cdc.gov/ncidod/EID/vol5no4/davis.htm. Accessed September 8, 2006.
62. Fong IW, Alibek K. Bioterrorism and Infectious Agents: A New Dilemma for the 21st Century. New York, NY: Springer; 2005.
63. Peters CJ, Hartley DM. Anthrax inhalation and lethal human infection. Lancet. 2002;359:710-711.
64. Barakat L, Quentzel H, Jernigan J, et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA. 2002;287:863-868.
65. Watson A, Keir D. Information on which to base assessments of risk from environments contaminated with anthrax spores. Epidemiol Infect. 1994;113:479-490.
66. World Health Organization. Health Aspects of Chemical and Biological Weapons. Geneva, Switzerland: World Health Organization; 1970.
67. Proliferation of Weapons of Mass Destruction. Washington, DC: Office of Technology Assessment, US Congress; 1993:53-55. Publication OTA-ISC-559.
68. Centers for Disease Control and Prevention. Use of anthrax vaccine in the United States. MMWR Morb Mortal Wkly Rep. 2000;49:1-15.
69. Webb GF. A silent bomb: the risk of anthrax as a weapon of mass destruction. Proc Natl Acad Sci U S A. 2003;100: 4355-4356.
70. Webb G. Being prepared: modeling the response to an anthrax attack. Ann Intern Med. 2005;142:667-668.
71. Friedlander A, Welkos S, Pitt M, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993;167:1239-1242.
72. Lipton E. US cancels order for 75 million doses of anthrax vaccine. New York Times. December 20, 2006:A23.
73. Fowler R, Sanders G, Bravata D, et al. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med. 2005;142:601-10.
74. Brookmeyer R, Johnson E, Bollinger R. Public health vaccination policies for containing an anthrax outbreak. Nature. 2004;432:901-904.
75. Wein L, Craft D, Kaplan E. Emergency response to an anthrax attack. Proc Natl Acad Sci U S A. 2003;100:4346-4351.
76. Little S. Anthrax vaccines, a development update. Biodrugs. 2005;19:233-245.
77. Friedlander A, Welkos S, Ivins B. Anthrax vaccines. Curr Top Microbiol Immunol. 2002;271:33-60.
78. Hearings Before the Subcommittee on Public Health of the Senate Committee on Health Education Labor and Pensions, Senate Hearing 107-440, 107th Congress, 1st Sess (October 9, 2001) (statement of Senator Tim Hutchinson, R-Ark).